


Base case and subgroup analyses

	Survival	(month)	LY	Incremental LY	QALY	Incremental QALY	Cost	Incremental Cost	ICER
	PFS	PD					(USD)	(USD)	(USD/QALY)
Overall (base case)									
Pembrolizumab + FP	12.67	12.54	2.10	0.57	1.38	0.38	99,975	67,109	176,479
FP	8.53	9.85	1.53		1.00		32,866		
PD-L1 CPS 10 or more									
Pembrolizumab + FP	13.74	13.50	2.27	0.87	1.48	0.58	103,741	73,183	126,862
FP	7.09	9.68	1.40		0.90		30,557		

Results of deterministic sensitivity analyses



Results of probabilistic sensitivity analyses(Scatter plot)

Incremental Cost (USD)

